# Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

> **NCT02139267** · PHASE2 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** GX-188E

## Key facts

- **NCT ID:** NCT02139267
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139267, "Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02139267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*